Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.

Original publication

DOI

10.1038/s41467-021-24062-3

Type

Journal

Nature communications

Publication Date

25/06/2021

Volume

12

Addresses

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. IAdetifa@kemri-wellcome.org.

Keywords

Humans, Immunoglobulin G, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Prevalence, Bayes Theorem, Seroepidemiologic Studies, Adolescent, Adult, Middle Aged, Kenya, Female, Male, Young Adult, Epidemics, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2